Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia

Autor:	Uwe Platzbecker, Maria Socorro O Portella, Honar Cherif, Moshe Mittelman, Michael Dickinson, Jeea Choi, Amit Verma, Pierre Fenaux, Pedro Marques Ramos, Paul Burgess
Jazyk:	angličtina
Rok vydání:	2018
Předmět:	Adult Male medicine.medical_specialty Clinical Trials and Observations Immunology Azacitidine Eltrombopag Platelet Transfusion Placebo Biochemistry Benzoates 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Double-Blind Method Risk Factors Internal medicine hemic and lymphatic diseases medicine Clinical endpoint Humans Adverse effect Aged Aged 80 and over business.industry Myelodysplastic syndromes Cell Biology Hematology Middle Aged medicine.disease Thrombocytopenia Hydrazines chemistry International Prognostic Scoring System 030220 oncology & carcinogenesis Myelodysplastic Syndromes Pyrazoles Female business Febrile neutropenia 030215 immunology medicine.drug
Popis:	Azacitidine treatment of myelodysplastic syndromes (MDSs) generally exacerbates thrombocytopenia during the first treatment cycles. A Study of Eltrombopag in Myelodysplastic Syndromes Receiving Azacitidine (SUPPORT), a phase 3, randomized, double-blind, placebo-controlled study, investigated the platelet supportive effects of eltrombopag given concomitantly with azacitidine. International Prognostic Scoring System intermediate-1, intermediate-2, or high-risk MDS patients with baseline platelets
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d66c2374746833a088bdccaf3c0bf7b https://europepmc.org/articles/PMC6337824/ Zobrazit plný text záznamu